Skip to main content
Log in

Torasemide

An Update of its Pharmacological Properties and Therapeutic Efficacy

  • Drug Evaluation
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Synopsis

The pharmacological properties and therapeutic use of the high-ceiling loop diuretic torasemide (torsemide) were previously reviewed in Drugs in 1991, the following being a re-examination of the role of the drug in the light of data that have subsequently become available (particularly in the management of oedematous disorders).

Torasemide produces a more prolonged water and electrolyte excretion than equipotent diuretic doses of furosemide (frusemide), but does not increase kaliuresis to the same extent. Dosages of torasemide of 2.5 to 5 mg/day do not affect plasma renin activity or aldosterone release to a clinically significant extent, although torasemide 20mg increases plasma renin levels, angiotensin II activity and urinary dopamine and prostaglandin E excretion.

Studies published since the previous review have confirmed the efficacy of low dosages of torasemide (2.5 to 5 mg/day) in the treatment of hypertension, and have shown it to be effective when administered orally at a dosage of 5 to 20 mg/day in the management of congestive heart failure. Dosages of up to 400 mg/day increased urinary volume excretion and natriuresis in patients with chronic renal failure. Bodyweight and peripheral oedema were reduced by torasemide 10 to 200 mg/day as monotherapy, and 5 to 20 mg/day when coadministered with spironolactone, in patients with nephrotic syndrome. Dosages of 10 to 40 mg/day, either as monotherapy or in conjunction with an aldosterone antagonist, reduced ascites, oedema and bodyweight in patients with hydropically decompensated liver failure.

Adverse effects due to torasemide are usually mild and transient in nature. No evidence of ototoxicity has been demonstrated in humans, and torasemide does not appear to affect blood glucose levels, serum uric acid concentrations, or serum potassium levels at dosages below 5 mg/day.

Thus, additional evidence has accumulated for the clinical efficacy of torasemide in the management of mild to moderate essential hypertension and oedematous conditions which require diuretic therapy. Further studies are now required to confirm the long term efficacy and tolerability of torasemide, and to investigate the place of the drug in therapy relative to cardiovascular agents other than furosemide and the thiazide diuretics.

Overview of Pharmacological Properties

Torasemide is a high-ceiling loop diuretic which inhibits renal tubular reabsorption of sodium and chloride in the thick ascending limb of the loop of Henle, resulting in a pronounced saluresis and diuresis. Urinary volume excretion and saluresis increase linearly with the logarithm of increasing torasemide dose, with a dose of torasemide between 10 and 20mg being equivalent in diuretic and saluretic potency over 24 hours to furosemide (frusemide) 40mg. Torasemide produces a more prolonged water and electrolyte excretion than furosemide, but does not increase kaliuresis to the same extent.

At a dosage of 2.5 mg/day, torasemide does not cause any overall increase in 24-hour natriuresis and is therefore nondiuretic. The effective use of torasemide at this dosage for the treatment of hypertension has been associated with the suggestion that increased natriuresis due to diuretic therapy does not play a part in the reduction of raised blood pressure.

In patients with chronic congestive heart failure (CHF) torasemide 10 to 20mg appears to produce greater saluresis and diuresis than furosemide 40mg, but urinary potassium excretion does not follow the dose-related increase seen with sodium and chloride excretion after single doses of torasemide of up to 20mg.

Torasemide 200mg, given intravenously, increased fractional urinary volume excretion to a greater extent than either intravenous furosemide 250mg or oral furosemide 500mg in patients with severe chronic renal impairment, and intravenous torasemide 60 to 100mg was superior in terms of fractional urinary volume excretion and fractional sodium excretion to intravenous furosemide 60mg in patients with moderate renal failure. Single-dose oral torasemide 20mg showed equivalent saluretic and diuretic potency to furosemide 40mg in a group of patients with liver cirrhosis and ascites. Torasemide 20mg increased cumulative 24-hour natriuresis and diuresis to a greater extent than furosemide 80mg, and torasemide 50mg exhibited a longer duration of action than furosemide 100mg in further studies of patients with hepatic cirrhosis.

Neither glomerular filtration rate nor creatinine clearance is affected by torasemide at dosages of up to 20 mg/day, although plasma renin levels, angiotensin II activity, urinary dopamine excretion and urinary prostaglandin E excretion are similarly increased by torasemide 20mg and furosemide 40mg. Torasemide 2.5 to 5 mg/day has no significant effect, however, on plasma renin activity or aldosterone release.

Intravenous torasemide 10 to 20mg is at least as effective as furosemide 20mg in reducing haemodynamic parameters of cardiac workload in patients with CHF, and single intravenous doses of torasemide 5 to 10mg reduced mean diastolic blood pressure by up to 25% in hypertensive patients. Torasemide may increase fasting plasma glucose levels at dosages above 5 mg/day, but no effects on serum triglycerides or serum total cholesterol levels are seen at dosages below 20 mg/day and 10 mg/day, respectively.

Torasemide is rapidly absorbed following oral administration, with the peak plasma concentration achieved within the first hour. Plasma protein binding is 97 to 99%, and the volume of distribution (calculated after intravenous administration) is 0.09 to 0.31 L/kg. Metabolism of torasemide involves hepatic biotransformation, with up to 25% of an intravenous dose being excreted unchanged in the urine. Three major metabolites occur in humans, but are not considered to exert clinically significant diuretic effects. The mean plasma elimination half-life of torasemide in healthy volunteers ranges from 2.2 to 5.1 hours. Torasemide exhibits similar pharmacokinetic properties in both young and elderly healthy volunteers, and no significant accumulation of the parent drug or its metabolites has occurred following oral administration of torasemide to patients with chronic renal failure at dosages of up to 200 mg/day for up to 11 days. Linear pharmacokinetics of torasemide have been observed after intravenous and oral administration of 20 to 200mg, and oral doses of 50 to 200mg to patients with renal failure and CHF, respectively.

Therapeutic use

Torasemide 2.5 to 5 mg/day has shown equivalent antihypertensive efficacy to hydrochlorothiazide 25 mg/day, and lacks the adverse metabolic and kaliuretic effects seen with natriuretic dosages of thiazide diuretics. Monotherapy with torasemide at the subdiuretic dosage of 2.5 mg/day normalised diastolic blood pressure in 60 to 76% of patients with mild to moderate essential hypertension, compared with 72 to 82% of patients receiving hydrochlorothiazide 25 to 50 mg/day, respectively, in combination with a potassium-sparing diuretic. Torasemide 2.5 mg/day has not been associated with any impairment of quality of life, based on assessments of daily activity and well-being.

Short term studies have shown orally administered torasemide 5 to 20 mg/day to decrease the severity of oedema and mean bodyweight to a greater extent than placebo or furosemide 40mg in patients with chronic CHF. Torasemide 20 mg/day also achieved a greater reduction in pre-existing oedema than furosemide 40 mg/day in patients with chronic CHF. Efficacy appeared to be maintained for 11 months in a longer term dose-ranging study using torasemide 5 to 20 mg/day.

Intravenous torasemide 400 to 800mg has shown equivalent diuretic efficacy to furosemide 1000mg in patients with acute renal failure, whereas oral administration of torasemide 200 to 400 mg/day increased urine volume and natriuresis similarly to furosemide 250 to 1000 mg/day in patients with chronic renal failure. Oral torasemide 50 to 200 mg/day appears to be at least as effective as furosemide 125 to 500 mg/day in reducing interdialysis weight gain and increasing diuresis and saluresis in patients with advanced renal impairment. Both torasemide 10 to 200 mg/day as monotherapy, and torasemide 5 to 20 mg/day plus spironolactone 50 to 200 mg/day, significantly reduced bodyweight and peripheral oedema after up to 13 weeks’ treatment in patients with nephrotic syndrome.

Monotherapy with torasemide up to 40 mg/day reduced abdominal girth due to ascites in patients with hydropically decompensated liver failure by up to 5.9%; furthermore, torasemide 10 to 20 mg/day coadministered with spironolactone 100 to 200 mg/day effectively reduced oedema, ascites and bodyweight in these patients. Torasemide 10 to 20 mg/day plus potassium canrenoate 200 mg/day decreased ascites and oedema in cirrhotic patients to a greater extent than either monotherapy with potassium canrenoate 400 mg/day for up to 7 days, or furosemide 25 to 50 mg/day plus potassium canrenoate 200 mg/day for 3 to 4 days. Addition of torasemide 10 to 40 mg/day to pre-existing therapy with spironolactone 50 to 400 mg/day improved ascites and oedema in 73% and 67% of patients, respectively, after 6 months’ treatment.

Tolerability

The adverse effects attributable to torasemide are usually mild and transient in nature and include fatigue, dizziness, headache, muscle cramps, lower back pain, skin rash, nausea and orthostatic hypotension. Although other adverse reactions, including pruritus, paraesthesia and chest pain have been noted after 48 weeks’ therapy with torasemide 2.5 to 5 mg/day, these are rare, and withdrawal from treatment due to torasemide-related drug reactions is seldom necessary. Analysis of pooled clinical trial data has shown the rate of occurrence of adverse events to be significantly less with torasemide than with combinations of hydrochlorothiazide and potassium-sparing diuretics in patients with hypertension.

No evidence of ototoxicity has been detected in humans after 4 weeks’ oral administration of torasemide at dosages of up to 400 mg/day. Torasemide does not appear to affect blood glucose levels, serum uric acid concentrations, or serum potassium levels at dosages below 5 mg/day.

Drug Interactions

Probenecid has been shown to reduce the diuretic and natriuretic effects, and to increase the plasma elimination half-life, of torasemide. Nonsteroidal anti-inflammatory drugs are also known to decrease the diuretic and natriuretic response to loop diuretics; indomethacin pretreatment appears to reduce diuresis and natriuresis due to torasemide under conditions of sodium restriction.

No pharmacokinetic interactions have been reported following coadministration of torasemide with digoxin, spironolactone, carvedilol or cimetidine. Torasemide does not appear to interfere with serum protein binding of either warfarin or phenprocoumon.

Dosage and Administratior

An oral dosage of torasemide 2.5 mg/day, increasing to 5 mg/day if necessary after 12 weeks is recommended for the management of mild to moderate essential hypertension. Oral dosages of torasemide 5 mg/day, increasing to 20 mg/day (the maximum recommended dosage being 40 mg/day), are recommended for patients with chronic CHF, and torasemide 5 to 40 mg/day may also be used in conjunction with an aldosterone antagonist such as spironolactone for the management of ascites secondary to hepatic cirrhosis. Oedema associated with nephrotic syndrome may be treated with torasemide 100mg coadministered with an aldosterone antagonist.

Intravenous administration of torasemide 20 to 200 mg/day is recommended in advanced chronic renal failure, and no dosage adjustment appears necessary in patients undergoing haemofiltration or haemodialysis. High-dosage intravenous torasemide (up to 800 mg/day) appears to be effective in converting oliguric acute renal failure to the polyuric form.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Friedel HA, Buckley MM-T. Torasemide: a review of its pharmacological properties and therapeutic potential. Drugs 1991; 41: 81–103

    Article  PubMed  CAS  Google Scholar 

  2. Beck FX, Sone M, Dorge A, et al. Effect of loop diuretics on organic osmolytes and cell electrolytes in the renal outer medulla. Kidney Int 1992 Oct; 42: 843–50

    Article  PubMed  CAS  Google Scholar 

  3. Noormohamed FH, Lant AF. Proximal renal tubular effects of loop diuretics, torasemide, bumetanide and frusemide [abstract]. Br J Clin Pharmacol 1994; 37: 478–9

    Google Scholar 

  4. Lambe R, Kennedy O, Kenny M, et al. Study of the tolerance and diuretic properties of torasemide following oral or intravenous administration to healthy volunteers. Eur J Clin Pharmacol 1986; 31 Suppl.: 9–14

    Article  PubMed  CAS  Google Scholar 

  5. Morris CL. Focus on torsemide: a new, potent, high-ceiling loop diuretic. Hosp Formul 1992; 27: 1167–77

    Google Scholar 

  6. Lameire N, Dodion L. Acute and chronic effects of torasemide in healthy volunteers. Arzneimittel Forschung 1988; 38: 167–71

    PubMed  CAS  Google Scholar 

  7. Dupont AG, Gerlo E, Van der Niepen P, et al. Renal pharmacodynamic effects of torasemide and furosemide in normal man. Arzneimittel Forschung 1988; 38: 172–5

    PubMed  CAS  Google Scholar 

  8. Reyes AJ, Leary WP, van der Byl K. Excretions of urinary fluid and solutes after single doses of furosemide and hydrochlorothiazide and of four different single doses of the diuretic torasemide in healthy subjects. In: Krück F, Mutschier E, Knauf H, editors. Torasemide: clinical pharmacology and therapeutic applications. Proceedings of the 2nd International Symposium on Torasemide, Munich, October 21-23, 1988. Progress in Pharmacology and Clinical Pharmacology, v. 8. Stuttgart, New York: Gustav Fischer Verlag, 1990: 47–71

    Google Scholar 

  9. Brater DC, Leinfelder J, Anderson SA. Clinical pharmacology of torasemide, anew loop diuretic. Clin Pharmacol Ther 1987; 42: 187–92

    Article  PubMed  CAS  Google Scholar 

  10. Lesne M. Comparison of the pharmacokinetics and pharmacodynamics of torasemide and furosemide in healthy volunteers. Arzneimittel Forschung 1988; 38: 160–3

    PubMed  CAS  Google Scholar 

  11. Reyes AJ, Leary WP. Renal excretory responses to single and repeated administration of diuretics in healthy subjects: clinical connotations. Cardiovasc Drugs Ther 1993; 7: 29–44

    Article  PubMed  Google Scholar 

  12. Reyes AJ. Effects of diuretics on outputs and flows of urine and urinary solutes in healthy subjects. Drugs 1991; 41 Suppl. 3: 35–59

    Article  PubMed  CAS  Google Scholar 

  13. Reyes AJ, Olhaberry JV, Crippa G. The decrease in the ‘volume factor’ as a possible determinant of the antihypertensive effect of diuretics. In: Puschett JB, Greenberg A, editors. Diuretics IV: chemistry, pharmacology and clinical applications. Amsterdam: Elsevier Science Publishers, 1993: 535–8

    Google Scholar 

  14. Achhammer I, Eberhard R. Comparison of serum potassium levels during long-term treatment of hypertensive patients with 2.5 mg torasemide/day or 50 mg triamterene/25 mg hydrochlorothiazide/day. In: Krück F, Mutschier E, Knauf H, editors. Torasemide: clinical pharmacology and therapeutic applications. Proceedings of the 2nd International Symposium on Torasemide, Munich, October 21-23, 1988. Progress in Pharmacology and Clinical Pharmacology, v. 8. Stuttgart, New York: Gustav Fischer Verlag, 1990: 211–20

    Google Scholar 

  15. Uchida T, Yamanaga K, Nishikawa M, et al. Anti-aldosteronergic effect of torasemide [abstract]. Naun Schmied Arch Pharmacol 1991; 344 Suppl. 2: R137

    Article  Google Scholar 

  16. Giebisch G, Klein-Robbenhaar G. Recent studies on the characterization of loop diuretics. J Cardiovasc Pharmacol 1993; 22 Suppl. 3:S1–S10

    Article  PubMed  CAS  Google Scholar 

  17. Patterson JH, Adams KF, Applefeld MM, et al. Torsemide in patients with chronic congestive heart failure: effects on body weight and electrolyte excretion. Boehringer Mannheim GmbH, data on file, 1993

  18. Hariman R, Bremner S, Kostis JB, et al. Comparison of intravenous torsemide and furosemide in congestive heart failure. Boehringer Mannheim GmbH, data on file, 1993

  19. Stroobandt R, Dodion L, Kesteloot H. Clinical efficacy of torasemide, a new diuretic, in patients with acute heart failure: a double blind comparison with furosemide. Arch Int Pharmacodyn Ther 1982; 260: 151–8

    PubMed  CAS  Google Scholar 

  20. Mourad G, Haecker W, Mion C. Dose-dependent salidiuretic efficacy of torasemide in comparison to furosemide and placebo in advanced renal failure. Arzneimittel Forschung 1988; 38: 205–8

    PubMed  CAS  Google Scholar 

  21. Klütsch K, Grosswendt J, Haecker W. Single dose comparison of torasemide and furosemide in patients with advanced renal failure. Arzneimittel Forschung 1988; 38(1): 200–4

    PubMed  Google Scholar 

  22. Knauf H, Mutschier E. Saluretic effect of the loop diuretic torasemide in chronic renal failure. Eur J Clin Pharmacol 1990; 39: 337–43

    Article  PubMed  CAS  Google Scholar 

  23. Kult J, Bölke T. Controlled clinical trial comparing the diuretic effect of single doses of torasemide (200 mg po) and furosemide (250 mg iv, 500 mg po) in patients with chronic renal failure. In: Puschett JB, Greenberg A, editors. Diuretics IV: chemistry, pharmacology and clinical applications. Amsterdam: Elsevier Science Publishers, 1993: 135–7

    Google Scholar 

  24. Kult J, Schulz W, Bölke T. Comparative placebo-controlled clinical trial on the acute diuretic and natriuretic effect of torasemide versus furosemide in patients with chronic renal failure. In: Puschett JB, Greenberg A, editors. Diuretics IV: chemistry, pharmacology and clinical applications. Amsterdam: Elsevier Science Publishers, 1993: 131–4

    Google Scholar 

  25. Brunner G, von Bergmann K, Häcker W, et al. Comparison of diuretic effects and pharmacokinetics of torasemide and furosemide after a single oral dose in patients with hydropically decompensated cirrhosis of the liver. Arzneimittel Forschung 1988; 38(1): 176–9

    PubMed  CAS  Google Scholar 

  26. Gerbes AL, Bertheau-Reitha U, Falkner C, et al. Advantages of the new loop diuretic torasemide over furosemide in patients with cirrhosis and ascites. A randomized, double blind crossover trial. J Hepatol 1993; 17: 353–8

    Article  PubMed  CAS  Google Scholar 

  27. Crippa G, Cassi A, Vergani F. Renal excretory pharmacodynamics of diuretics in hepatic diseases. In: Reyes AJ, editor. Diuretics: clinical pharmacology and uses in cardiovascular medicine, nephrology and hepatology. Progress in Pharmacology and Clinical Pharmacology, v. 9. Stuttgart, Jena, New York: Gustav Fischer Verlag, 1992: 597–617

    Google Scholar 

  28. van Ganse E, Douchamps J, Deger F, et al. Failure of indomethacin to impair the diuretic and natriuretic effects of the loop diuretic torasemide in healthy volunteers. Eur J Clin Pharmacol 1986; 31 Suppl.: 43–7

    Article  PubMed  Google Scholar 

  29. Herchuelz A, Derenne F, Deger F, et al. Interaction between nonsteroidal anti-inflammatory drugs and loop diuretics: modulation by sodium balance. J Pharmacol Exp Ther 1989; 248: 1175–81

    PubMed  CAS  Google Scholar 

  30. Cuvelier R, Pellegrin P, Lesne M, et al. Site of action of torasemide in man. Eur J Clin Pharmacol 1986; 31 Suppl.: 15–9

    Article  PubMed  CAS  Google Scholar 

  31. Scheen AJ, Vancrombreucq JC, Delarge J, et al. Diuretic activity of torasemide and furosemide in chronic heart failure: a comparative double blind cross-over study. Eur J Clin Pharmacol 1986; 31: 35–42

    Article  PubMed  Google Scholar 

  32. Spieker C, Ziedek W, Vetter H. Acute effects of torasemide on the renin-activity and on intracellular electrolytes in hypertensive patients. In: Krück F, Mutschler E, Knauf H, editors. Torasemide: clinical pharmacology and therapeutic applications. Proceedings of the 2nd International Symposium on Torasemide, Munich, October 21-23, 1988. Progress in Pharmacology and Clinical Pharmacology, v. 8. Stuttgart, New York: Gustav Fischer Verlag, 1990: 221–6

    Google Scholar 

  33. Uchida T, Kido H, Yamanaga K, et al. A novel loop diuretic, torasemide, inhibits thromboxane A2-induced contraction in the isolated canine coronary artery. Prostaglandins Leukot Essent Fatty Acids 1992; 45: 121–4

    Article  PubMed  CAS  Google Scholar 

  34. Langbehn A-F, Achhammer I, Bölke T. Acute hemodynamic effects of 20mg torasemide and 20mg furosemide given intravenously to patients with congestive heart failure. In: Krück F, Mutschler E, Knauf H, editors. Torasemide: clinical pharmacology and therapeutic applications. Proceedings of the 2nd International Symposium on Torasemide, Munich, October 21-23, 1988. Progress in Pharmacology and Clinical Pharmacology, v. 8. Stuttgart, New York: Gustav Fischer Verlag, 1990: 147–55

    Google Scholar 

  35. Fiehring H, Achhammer I. Influence of 10mg torasemide i.v. and 20mg furosemide i.v. on the intracardiac pressures in patients with heart failure at rest and during exercise. In: Krück F, Mutschler E, Knauf H, editors. Torasemide: clinical pharmacology and therapeutic applications. Proceedings of the 2nd International Symposium on Torasemide, Munich, October 21–23, 1988. Progress in Pharmacology and Clinical Pharmacology, v. 8. Stuttgart, New York: Gustav Fischer Verlag, 1990: 97–104

    Google Scholar 

  36. Podszus T, Piesche L. Effect of torasemide on pulmonary and cardiac haemodynamics after oral treatment of chronic heart failure. In: Krück F, Mutschier E, Knauf H, editors. Torasemide: clinical pharmacology and therapeutic applications. Proceedings of the 2nd International Symposium on Torasemide, Munich, October 21–23, 1988. Progress in Pharmacology and Clinical Pharmacology, v. 8. Stuttgart, New York: Gustav Fischer Verlag, 1990: 157–66

    Google Scholar 

  37. Podszus T, Wagner U, Ploch T. Clinical and haemodynamic effects of long-term treatment with torasemide in congestive heart failure. Cardiology 1994; 84 Suppl. 2: 124–30

    Article  PubMed  Google Scholar 

  38. Russo D, Gazzotti RM, Testa A. Torasemide, a new loop diuretic, in patients with chronic renal failure. Nephron 1990; 55: 141–5

    Article  PubMed  CAS  Google Scholar 

  39. Staub F, Berger S, Stoffel M, et al. Therapeutical efficacy of torasemide in acidosis-induced swelling of glial cells and in vasogenic brain edema in vivo. In: Puschett JB, Greenberg A, editors. Diuretics IV: chemistry, pharmacology and clinical applications. Amsterdam: Elsevier Science Publishers, 1993: 811–6

    Google Scholar 

  40. Plangger C. Effect of torasemide on intracranial pressure, mean systemic arterial pressure and cerebral perfusion pressure in experimental brain edema of the rat. Acta Neurol Scand 1992; 86: 252–5

    Article  PubMed  CAS  Google Scholar 

  41. Weinberger MH. Mechanisms of diuretic effects on carbohydrate tolerance, insulin sensitivity and lipid levels. Eur Heart J 1992; 13 Suppl. G: 5–9

    Article  PubMed  CAS  Google Scholar 

  42. Barr WH, Smith HL, Karnes HT, et al. Torasemide dose-proportionality of pharmacokinetics and pharmacodynamics. In: Krück F, Mutschier E, Knauf H, editors. Torasemide: clinical pharmacology and therapeutic applications. Proceedings of the 2nd International Symposium on Torasemide, Munich, October 21–23, 1988. Progress in Pharmacology and Clinical Pharmacology, v. 8. Stuttgart, New York: Gustav Fischer Verlag, 1990: 29–38

    Google Scholar 

  43. Brater DC. Clinical pharmacology of loop diuretics. Drugs 1991; 41 Suppl. 3: 14–22

    Article  PubMed  Google Scholar 

  44. Neugebauer G, Besenfelder E, von Möllendorf E. Pharmacokinetics and metabolism of torasemide in man. Arzneimittel Forschung 1988; 38: 164–6

    PubMed  CAS  Google Scholar 

  45. Schwartz S, Brater DC, Pound D, et al. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide in patients with cirrhosis. Clin Pharmacol Ther 1993; 54: 90–7

    Article  PubMed  CAS  Google Scholar 

  46. Clerckx-Braun F, Lesne M. Priarmacokinetic study of a new diuretic: torasemide in man [in French]. J Pharm Belg 1980; 35: 223–4

    PubMed  CAS  Google Scholar 

  47. Knauf H, Spahn H, Mutschier E. The loop diuretic torasemide in chronic renal failure. Pharmacokinetics and pharmacodynamics. Drugs 1991; 41 Suppl. 3: 23–34

    Article  PubMed  Google Scholar 

  48. Lesne M, Clerckx-Braun F, Duhoux P, et al. Pharmacokinetic study of torasemide in humans: an overview of its diuretic effect. Int J Clin Pharmacol Ther Toxicol 1982; 20: 382–7

    PubMed  CAS  Google Scholar 

  49. Kramer WG, Rudy DW, Gehr TWB, et al. Torsemide pharmacokinetics and pharmacodynamics in patients with chronic renal insufficiency. In: Puschett JB, Greenberg A, editors. Diuretics IV: chemistry, pharmacology and clinical applications. Amsterdam: Elsevier Science Publishers, 1993: 107–11

    Google Scholar 

  50. Gehr TWB, Rudy DW, Matzke GR, et al. The pharmacokinetics of intravenous and oral torsemide in patients with chronic renal insufficiency. Clin Pharmacol Ther 1994; 56: 31–8

    Article  PubMed  CAS  Google Scholar 

  51. Barr WH, Smith HL, Karnes HT, et al. Comparison of bioavailability, pharmacokinetics and pharmacodynamics of torasemide in young and elderly healthy volunteers. In: Krück F, Mutschier E, Knauf H, editors. Torasemide: clinical pharmacology and therapeutic applications. Proceedings of the 2nd International Symposium on Torasemide, Munich, October 21-23,1988. Progress in Pharmacology and Clinical Pharmacology, v. 8. Stuttgart, New York: Gustav Fischer Verlag, 1990: 15–28

    Google Scholar 

  52. Grabensee B. Efficacy of oral torasemide (TS) and furosemide (FS) in the treatment of chronic renal failure [abstract]. 2nd International Symposium on Torasemide, Munich, October 21-23, 1988

  53. Krämer BK, Schwab A, Braun N, et al. Metabolism of torasemide during acute and chronic dosing in renal failure. In: Puschett JB, Greenberg A, editors. Diuretics IV: chemistry, pharmacology and clinical applications. Amsterdam: Elsevier Science Publishers, 1993: 103–5

    Google Scholar 

  54. von Möllendorff E, Neugebauer G. Pharmacokinetics of torasemide in patients with congestive heart failure. In: Krück F, Mutschier E, Knauf H, editors. Torasemide: clinical pharmacology and therapeutic applications. Proceedings of the 2nd International Symposium on Torasemide, Munich, October 21-23, 1988. Progress in Pharmacology and Clinical Pharmacology, v. 8. Stuttgart, New York: Gustav Fischer Verlag, 1990:73–80

    Google Scholar 

  55. Vargo D, Kramer WG, Black PK, et al. The pharmacodynamics of torsemide in patients with congestive heart failure. Clin Pharmacol Ther 1994; 56: 48–54

    Article  PubMed  CAS  Google Scholar 

  56. Achhammer I, Metz P. Low dose loop diuretics in essential hypertension. Experience with torasemide. Drugs 1991; 41 Suppl. 3: 80–91

    Article  PubMed  Google Scholar 

  57. Luft FC. Torasemide in the treatment of arterial hypertension. J Cardiovasc Pharmacol 1993; 22 Suppl. 3: S32–9

    Article  PubMed  Google Scholar 

  58. Porcellati C, Verdecchia P, Schillaci G, et al. La torasemide, nuovo diuretico dell’ansa, nel trattamento dell’ipertensione arteriosa. Studio controllato in doppia cecità [in Italian]. Basi Razion Ter 1990; 20: 407–10

    Google Scholar 

  59. Bölke T, Achhammer I, Meyer-Sabellek WA. Blutdrucksenkung und metabolische Veränderungen bei essentiellen Hypertonikern nach Langzeitgabe unterscheidlicher Diuretika [in German]. Hochdruck 1990; 9: 40–1

    Google Scholar 

  60. Bölke T, Achhammer I, Meyer-Sabelleck WA, et al. Tages- und Nachtrythmik ambulanter 24h- Blutdruckwerte von älteren essentiellen Hypertonikern bei Therapie mit verschiedenen Diuretika [in German]. Hochdruck 1990; 10: 40

    Google Scholar 

  61. Goto Y, Tamachi H, Honma Y. Effect of a new loop diuretic, GJ-1090 (torasemide) on metabolism of lipid and carbohydrate in patients with essential hypertension. A multiclinic study [in Japanese]. Rinsho Iyaku 1994; 10 Suppl. 5: 205–23

    Google Scholar 

  62. Baumgart P. Torasemide in comparison with thiazides in the treatment of hypertension. Cardiovasc Drugs Ther 1993; 7: 63–8

    Article  PubMed  Google Scholar 

  63. Spannbrucker N, Achhammer I, Metz P, et al. Comparative study on the antihypertensive efficacy of torasemide and indapamide in patients with essential hypertension. Arzneimittel Forschung 1988; 38: 190–3

    PubMed  CAS  Google Scholar 

  64. Reyes AJ, Chiesa PD, Santucci MR, et al. Hydrochlorothiazide versus a non-diuretic dose of torasemide as once-daily antihypertensive monopharmacotherapy in elderly patients. A randomized and double-blind study. In: Krück F, Mutschler E, Knauf H, editors. Torasemide: clinical pharmacology and therapeutic applications. Proceedings of the 2nd International Symposium on Torasemide, Munich, October 21–23, 1988. Progress in Pharmacology and Clinical Pharmacology, v. 8. Stuttgart, New York: Gustav Fischer Verlag, 1990: 183–209

    Google Scholar 

  65. Ferreira MI, Alcocer L, Leary WP, et al. Quality of life during antihypertensive therapy with diuretics: critical reappraisal. In: Reyes AJ, editor. Diuretics: clinical pharmacology and uses in cardiovascular medicine, nephrology and hepatology. Progress in Pharmacology and Clinical Pharmacology, v. 9. Stuttgart, Jena, New York: Gustav Fischer Verlag, 1992: 515–31

    Google Scholar 

  66. Kruck F. Acute and long term effects of loop diuretics in heart failure. Drugs 1991; 41 Suppl. 3: 60–8

    Article  PubMed  Google Scholar 

  67. Achhammer I. Long term efficacy and tolerance of torasemide in congestive heart failure. In: Krück F, Mutschler E, Knauf H, editors. Torasemide: clinical pharmacology and therapeutic applications. Proceedings of the 2nd International Symposium on Torasemide, Munich, October 21-23, 1988. Progress in Pharmacology and Clinical Pharmacology, v. 8. Stuttgart, New York: Gustav Fischer Verlag, 1990: 127–36

    Google Scholar 

  68. Düsing R, Piesche L. Second line therapy of congestive heart failure with torasemide. In: Krück F, Mutschler E, Knauf H, editors. Torasemide: clinical pharmacology and therapeutic applications. Proceedings of the 2nd International Symposium on Torasemide, Munich, October 21–23, 1988. Progress in Pharmacology and Clinical Pharmacology, v. 8. Stuttgart, New York: Gustav Fischer Verlag, 1990: 105–20

    Google Scholar 

  69. Goebel K-M. Six-week study of torsemide in patients with congestive heart failure. Clin Ther 1993 Npv-Dec; 15: 1051–9

    PubMed  CAS  Google Scholar 

  70. Lehnert H, Schmitz H, Beyer J, et al. Controlled clinical trial investigating the influence of torasemide and furosemide on carbohydrate metabolism in patients with cardiac failure and concomitant type II diabetes. In: Puschett JB, Greenberg A, editors. Diuretics IV: chemistry, pharmacology and clinical applications. Amsterdam: Elsevier Science Publishers, 1993: 271–4

    Google Scholar 

  71. Piesche L, Bölke T. Comparative clinical trial investigating possible interactions of torasemide (20 mg o.d.) or furosemide (40 mg o.d.) with phenprocoumon in patients with congestive heart failure. In: Puschett JB, Greenberg A, editors. Diuretics IV: chemistry, pharmacology and clinical applications. Amsterdam: Elsevier Science Publishers, 1993: 267–70

    Google Scholar 

  72. Stauch M, Stiehl L. Controlled, double-blind clinical trial on the efficacy and tolerance of torasemide in comparison with furosemide in patients with congestive heart failure — a multicenter study. In: Krück F, Mutschler E, Knauf H, editors. Torasemide: clinical pharmacology and therapeutic applications. Proceedings of the 2nd international Symposium on Torasemide, Munich, October 21-23, 1988. Progress in Pharmacology and Clinical Pharmacology, v. 8. Stuttgart, New York: Gustav Fischer Verlag, 1990: 121–6

    Google Scholar 

  73. Kindler J. Torasemide in advanced renal failure. Cardiovasc Drugs Ther 1993; 7: 75–80

    Article  PubMed  Google Scholar 

  74. Risler T, Kramer B, Muller GA. The efficacy of diuretics in acute and chronic renal failure. Focus on torasemide. Drugs 1991; 41 Suppl. 3: 69–79

    Article  PubMed  Google Scholar 

  75. Russo D, Memoli B, Andreucci VE. The place of loop diuretics in the treatment of acute and chronic renal failure. Clin Nephrol 1992; 38 Suppl. 1: S69–73

    PubMed  Google Scholar 

  76. Andreucci VE, Russo D, Memoli B, et al. Efficacy of i.v. torasemide in the treatment of acute and chronic high grade renal failure. In: Krück F, Mutschler E, Knauf H, editors. Torasemide: clinical pharmacology and therapeutic applications. Proceedings of the 2nd International Symposium on Torasemide, Munich, October 21–23,1988. Progress in Pharmacology and Clinical Pharmacology, v. 8. Stuttgart, New York: Gustav Fischer Verlag, 1990: 229–38

    Google Scholar 

  77. Sterz R, Holtbrügge W. Controlled clinical trial investigating the efficacy of torasemide in comparison to furosemide in acute renal failure. Boehringer Mannheim GmbH data on file. Report no. 037, 1988

  78. Clasen W, Khartabil T, Imm St, et al. Torasemide for diuretic treatment of advanced chronic renal failure. Arzneimittel Forschung 1988; 38(1): 209–11

    PubMed  CAS  Google Scholar 

  79. Kult J, Hacker W, Glocke M, Comparison of efficacy and tolerance of different oral doses of torasemide and furosemide in patients with advanced chronic renal failure. Arzneimittel Forschung 1988; 38: 212–4

    PubMed  CAS  Google Scholar 

  80. Schulz W, Dörfler A, Stiehl L, et al. Double-blind clinical trial investigating the efficacy and long-term tolerance of torasemide 200mg p.o. compared with furosemide 500mg p.o. and placebo p.o. in patients with chronic renal failure on hemodialysis, a multicentre study. In: Krück F, Mutschler E, Knauf H, editors. Torasemide: clinical pharmacology and therapeutic applications. Proceedings of the 2nd International Symposium on Torasemide, Munich, October 21–23, 1988. Progress in Pharmacology and Clinical Pharmacology, v. 8. Stuttgart, New York: Gustav Fischer Verlag, 1990: 249–58

    Google Scholar 

  81. Stolear IC, Achhammer I, Georges B. Efficacy of torasemide in the treatment of patients with high grade renal failure on dialysis. In: Krück F, Mutschler E, Knauf H, editors. Torasemide: clinical pharmacology and therapeutic applications. Proceedings of the 2nd International Symposium on Torasemide, Munich, October 21–23, 1988. Progress in Pharmacology and Clinical Pharmacology, v. 8. Stuttgart, New York: Gustav Fischer Verlag, 1990: 259–68

    Google Scholar 

  82. Boesken WH, Kult J, Eberwein B. Efficacy and safety of torasemide (10–200 mg/day p.o.) in the treatment of edema in patients with nephrotic syndrome. In: Puschett JB, Greenberg A, editors. Diuretics IV: chemistry, pharmacology and clinical applications. Amsterdam: Elsevier Science Publishers, 1993:51–4

    Google Scholar 

  83. Franz M, Falger S,Traindl O, et al. Clinical experience with a new diuretic. In: Andreucci VE, Dal Canton A, editors. Current Therapy in Nephrology. Mailand: Wichtig Editore, 1992: 99–102

    Google Scholar 

  84. Gentilini P, Laffi G. Pathophysiology and treatment of ascites and the hepatorenal syndrome. Baillieres Clin Gastroenterol 1992; 6: 581–607

    Article  PubMed  CAS  Google Scholar 

  85. Gentilini P, Laffi G, La Villa G, et al. Torasemide in the treatment of patients with cirrhosis and ascites. Cardiovasc Drugs Ther 1993; 7: 81–5

    Article  PubMed  Google Scholar 

  86. Brunner G, Estrada E, Piesche L. Efficacy and safety of torasemide (5 to 40 mg o.d.) in the treatment of edema in patients with hydropically decompensated liver failure. In: Puschett JB, Greenberg A, editors. Diuretics IV: chemistry, pharmacology and clinical applications. Amsterdam: Elsevier Science Publishers, 1993: 27–30

    Google Scholar 

  87. Fiaccadori F, Pedretti G, Pasetti G, et al. Torasemide versus furosemide in cirrhosis: a long-term, double-blind, randomized clinical study. Clin Investig 1993; 71: 579–84

    Article  PubMed  CAS  Google Scholar 

  88. Laffi G, Marra F, Buzzelli G, et al. Comparison of the effects of torasemide and furosemide in nonazotemic cirrhotic patients with ascites: a randomized, double-blind study. Hepatology 1991; 13: 1101–5

    Article  PubMed  CAS  Google Scholar 

  89. Knauf E, Mutschier H. Liver cirrhosis with ascites: pathogenesis of resistance to diuretics and long-term efficacy and safety of torasemide. Cardiology 1994; 84 Suppl. 2: 87–98

    Article  PubMed  Google Scholar 

  90. Brunner G, Chang J, Gonzales J, et al. Treatment of cirrhotic ascites/edema: a therapeutic approach with torasemide-spironolactone. In: Puschett JB, Greenberg A, editors. Diuretics: chemistry, pharmacology, and clinical applications. New York: Elsevier Science Publishing Co, 1990: 402–4

    Google Scholar 

  91. Elia G, Ferrari C, Degli Antoni A, et al. A short-term clinical study of a new loop diuretic, torasemide, in cirrhosis. Ital J Gastroenterol 1989; 21: 324–8

    Google Scholar 

  92. Piesche L, Glocke M. Clinical trial of the efficacy of torasemide and potassium canrenoate in hydropically decompensated liver failure. Controlled double-blind study in three independent groups. Boehringer Mannheim GmbH, data on file. 032, 1986

  93. Broekhuysen J, Deger F, Douchamps J, et al. Torasemide, a new potent diuretic. Double-blind comparison with furosemide. Eur J Clin Pharmacol 1986; 31 Suppl.: 29–34

    Article  PubMed  Google Scholar 

  94. Mocks J, Hiemstra S. Torasemide adverse events report. Boehringer Mannheim GmbH data on file, 1990

  95. Klinke R, Mertens M. Quantitative assessment of torasemide ototoxicity. Arzneimittel Forschung 1988; 38: 153–5

    PubMed  CAS  Google Scholar 

  96. Ambroes Y, Ronflette I, Dodion L. Diuretic activity, safety and pharmacokinetics of torasemide during chronic treatment in normal subjects. Eur J Clin Pharmacol 1986; 31 Suppl.: 1–7

    Article  PubMed  CAS  Google Scholar 

  97. Krämer BK, Ress KM, von Möllendorff E, et al. Influence of torasemide on serum level and renal elimination of digoxin in healthy volunteers. In: Krück F, Mutschier E, Knauf H, editors. Torasemide: clinical pharmacology and therapeutic applications. Proceedings of the 2nd International Symposium on Torasemide, Munich, October 21–23, 1988. Progress in Pharmacology and Clinical Pharmacology, v. 8. Stuttgart, New York: Gustav Fischer Verlag, 1990: 39–46

    Google Scholar 

  98. von Möllendorff E, Kaufmann B. Study of possible kinetic interactions after administration of torasemide and spironolactone (fixed combination as well as single substances) after a standard meal. Boehringer Mannheim GmbH data on file. Report no. N21, 1988

  99. Lücker PW, Adolph S. Steady state pharmacokinetic interactions of torasemide (INN) (diuretic) and carvedilol (INN) (beta-blocker) after combined administration. Boehringer Mannheim GmbH data on file. Report no. N17, 1987

  100. Kramer WG. Lack of effect of cimetidine on torsemide pharmacokinetics and pharmacodynamics in healthy subjects. In: Puschett JB, Greenberg A, editors. Diuretics IV: chemistry, pharmacology and clinical applications. Amsterdam: Elsevier Science Publishers, 1993: 361–4

    Google Scholar 

  101. Böhm E, Höick J-P, Schaumann W. Influence of cholestyramine on the absorption of 14C-torasemide in rats. Boehringer Mannheim GmbH data on file. Report no. L12, 1990

  102. Rudy DW, Gehr TWB, Matzke GR, et al. The pharmacodynamics of intravenous and oral torsemide in patients with chronic renal insufficiency. Clin Pharmacol Ther 1994; 56: 39–47

    Article  PubMed  CAS  Google Scholar 

  103. Loute G, Adam A, Ers P, et al. The influence of haemodialysis and haemofiltration on the clearance of torasemide in renal failure. Eur J Clin Pharmacol 1986; 31 Suppl.: 53–5

    Article  PubMed  Google Scholar 

  104. Johnston CL The place of diuretics in the treatment of hypertension in 1993: can we do better?. Clin Exp Hypertens 1993; 15: 1239–55

    Article  PubMed  CAS  Google Scholar 

  105. New trials in older hypertensives [editorial]. Lancet 1991; 338: 1299-300

  106. Menard J, Chatellier G. Co-operative study of systolic arterial hypertension in the elderly [in French]. Presse Med 1992; 21: 1762–7

    PubMed  CAS  Google Scholar 

  107. Passmore AP, Whitehead EM, Crawford V, et al. The antihyper- tensive and metabolic effects of low and conventional dose cyclopenthaizide in type II diabetics with hypertension. Q J Med 1991; 81: 919–28

    PubMed  CAS  Google Scholar 

  108. Moser M. Current hypertension management: separating fact from fiction. Cleve Clin J Med 1993; 60: 27–37

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Additional information

Various sections of the manuscript reviewed by: V.E. Andreucci, Cattedra di Nefrologia Medica, Faculty of Medicine and Surgery, University of Naples, Naples, Italy; D.C. Brater, Department of Medicine, Indiana University Medical Center, Indianapolis, Indiana, USA; K.S. Channer, Department of Cardiology, Royal Hallamshire Hospital, Sheffield, England; A.G. Dupont, Department of Pharmacology and Therapeutics, Free University of Brussels, Brussels, Belgium; T.W.B. Gehr, Division of Nephrology, Medical College of Virginia Hospitals, Virginia Commonwealth University, Richmond, Virginia, USA; P. Gentilini, Istituto di Medicina Interna, University of Florence, Florence, Italy; G.D. Johnston, Department of Therapeutics and Pharmacology, Queen’s University of Belfast, Belfast, Northern Ireland; J. Kindler, Department of Internal Medicine, Kreiskrankenhaus Marienhöhe, Würselen, Germany; F. Krück, Medizinische Universitäts-Poliklinik, Bonn, Germany; A.F. Lant, Department of Clinical Pharmacology and Therapeutics, Charing Cross and Westminster Medical Schools, Westminster Hospital, London, England; T.O. Morgan, Department of Physiology, University of Melbourne, Melbourne, Victoria, Australia; M. Moser, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA; A.J. Reyes, Institute of Cardiovascular Theory, Montevideo, Uruguay.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dunn, C.J., Fitton, A. & Brogden, R.N. Torasemide. Drugs 49, 121–142 (1995). https://doi.org/10.2165/00003495-199549010-00009

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199549010-00009

Keywords

Navigation